Hepatitis C Genotypes 2008
May-April
Limitations of an 8-week Course of Pegylated
interferon plus Ribavirin for Genotype 2 Hepatitis C Patients with Rapid
Virological Response
FACTORS PREDICTIVE OF RELAPSE IN GENOTYPE 2 AND 3 PTS
TREATED FOR 12 WEEKS WITH PEGIFN ALFA 2B AND WEIGHT BASED RIBAVIRIN
COMBINATION -
RIBAVIRIN CONCENTRATION AT WEEK FOUR IS AN INDEPENDEND
PREDICTOR FOR SUSTAINED VIROLOGICAL RESPONSE AFTER TREATMENT OF HEPATITIS C
GENOTYPE 2/3 (NORDYNAMIC TRIAL) -
Vertex and Tibotec Start Phase 3 Study of Telaprevir
for Treatment-Naive Genotype 1 Hepatitis C Patients
Telaprevir plus Pegylated Interferon and Ribavirin
Allows Shorter Therapy for Patients with Genotype 1 HCV
Vertex Announces Positive Interim Results
with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who
Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin
Treatment
Telaprevir-Based PROVE Studies Show
Significantly Higher SVR Rates in Treatment-Naive Genotype 1 Hepatitis C
Patients in Half the Time of Current Treatments
March-February
Genetic Variations in HCV Genotype 3 Core Protein
Promote Liver Fat Accumulation
-
Asians with HCV Genotype 3 Do Not Respond as Well as
Caucasians to Interferon-based Therapy
Insulin Resistance Linked to Lower Treatment Response
in Genotype 2/3 Patients
Liver Steatosis Is Common in Hepatitis C Patients,
Especially Those with Genotype 3
Duration of Pegylated Interferon plus Ribavirin for
HCV Genotypes 2 and 3
-
January
Shorter HCV treatment shows notable success
An Updated Report on Hepatitis C Genotypes
Pegylated Interferon plus Ribavirin in the Treatment
of Chronic Hepatitis C Genotype 4
Insulin resistance and response to therapy in patients infected with chronic
hepatitis C virus genotypes 2 and 3 -
Hepatitis C genotype change after successful treatment
indicates re-infection
2007
2006
2005 Index Genotype Research
2004 Thru 2001 Index of all Genotype Research
|
